https://www.selleckchem.com/pr....oducts/nedisertib.ht
As most clinical trials have been performed in more symptomatic and higher-risk patients, evidence regarding treatment in patients with Global Initiative for Chronic Obstructive Lung Disease (GOLD) group A chronic obstructive pulmonary disease (COPD) is limited. We assessed the distribution of inhaler treatment and sought to investigate the association between inhaled corticosteroid (ICS) use and future exacerbation in GOLD group A COPD patients. Patients with GOLD group A COPD who received maintenance inhalers were identified from a
Like
Comment
Share
